dc.contributor.author | GUNEY-TEFEKLI, Esra | |
dc.contributor.author | URGANCIOGLU, Meri | |
dc.contributor.author | Tugal-Tutkun, Ilknur | |
dc.date.accessioned | 2021-03-06T20:20:45Z | |
dc.date.available | 2021-03-06T20:20:45Z | |
dc.date.issued | 2006 | |
dc.identifier.citation | Tugal-Tutkun I., GUNEY-TEFEKLI E., URGANCIOGLU M., "Results of interferon-alfa therapy in patients with Behcet uveitis", GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, cilt.244, ss.1692-1695, 2006 | |
dc.identifier.issn | 0721-832X | |
dc.identifier.other | vv_1032021 | |
dc.identifier.other | av_f9d6d54b-a116-489d-8431-fca1080b4834 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/163609 | |
dc.identifier.uri | https://doi.org/10.1007/s00417-006-0346-y | |
dc.description.abstract | Purpose: To report on the results of interferon-alpha 2a (IFN alpha) treatment in patients with Behcet uveitis unresponsive to conventional immunosuppressive therapy. Methods: We retrospectively analyzed the medical records of 44 patients who had been treated with IFN alpha between September 2001 and May 2005. The initial dose of IFN alpha was 6 MU/day in 37 patients (84.1%) and 3 MU/day in 7 patients (15.9%), and was gradually tapered after ocular inflammation was suppressed. Immunosuppressive agents were discontinued. Oral corticosteroids were discontinued or maintained at a dosage of less than 10 mg prednisone equivalent per day. Main outcome measures were recurrence of posterior or panuveitis attacks and changes in visual acuity. Results: Sixteen patients (36.4%) remained relapse free during treatment, whereas 28 (63.6%) patients had recurrent uveitis attacks. Four of these were considered treatment failures and were switched to other treatments. In the remaining 40 patients, the mean duration of treatment was 12.4 +/- 10.8 months (range 3-45 months). In 9 of 40 patients (22.5%) treatment could be discontinued 22.2 +/- 13.4 months after therapy, and 8 (20%) of these patients had sustained remission for up to 24 months. Three patients (7.5%) were switched to other therapies because of side effects. The frequency of uveitis attacks per 6 months was reduced from 1.6 +/- 1.2 to 0.8 +/- 0.9 in 26 patients who had a minimum follow-up of 6 months before and after IFN alpha therapy (p < 0.05). There was a significant improvement in visual acuity and this was preserved throughout follow-up in 38 (95%) of 40 patients. Conclusions: A partial or complete response was obtained with IFN alpha therapy in 91% of Turkish patients with Behcet uveitis refractory to conventional immunosuppressive treatment. Our results suggest that there may be differences in therapeutic efficacy and side-effect profile of IFN alpha in different patient populations. Comparative studies are needed to investigate this hypothesis. | |
dc.language.iso | eng | |
dc.subject | Cerrahi Tıp Bilimleri | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Göz Hastalıkları ve Cerrahisi | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | Tıp | |
dc.subject | OFTALMOLOJİ | |
dc.title | Results of interferon-alfa therapy in patients with Behcet uveitis | |
dc.type | Makale | |
dc.relation.journal | GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | |
dc.contributor.department | İstanbul Üniversitesi , , | |
dc.identifier.volume | 244 | |
dc.identifier.issue | 12 | |
dc.identifier.startpage | 1692 | |
dc.identifier.endpage | 1695 | |
dc.contributor.firstauthorID | 25189 | |